Crossmark

Risk-benefits assessment of tamoxifen or raloxifene as chemoprevention for risk reduction of breast cancer among BRCA1 and BRCA2 carriers: a meta-analysis

Crossref DOI link: https://doi.org/10.1038/s41598-025-89915-z

Published Online: 2025-02-25

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Alwashmi, Ameen S. S.

Khan, Najeeb Ullah

Chen, Tianhui
License Information

Text and Data Mining valid from 2025-02-25

Version of Record valid from 2025-02-25
More Information

Article History

Received: 23 November 2024

Accepted: 10 February 2025

First Online: 25 February 2025

Declarations

:

: The authors declare no competing interests.

Document is current

Any future updates will be listed below